Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Samsung Medical Center
Modality
Small molecule
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05742438CT.gov Effects of Dexmedetomidine/Lidocaine/Intrathecal Morphine on Cancer Metastasis Biomarker After Colorectal Surgery | — | Completed | — | — | — |
NCT05069311CT.gov Effects of Multimodal Analgesia on Serum MCP-1, BDNF, and MiRNA-124 in Hysterectomy Surgery | — | Completed | — | — | — |
NCT04613167CT.gov Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inflammatory Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nepenthe (this asset) | Samsung Medical Center | N/A | D · 30 |
| Vildagliptin | Rio de Janeiro State University | P4 | BB |
| Methoxy Polyethylene Glycol-Epoetin Beta | Taipei Veterans General Hospital, Taiwan | P4 | BB |
| Pitavastatin | Aichi Gakuin University | P4 | BB |
| Sufentanyl | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
| Sitagliptin | University of Southern California | P3 | BB |
| Oxycodone | The First Affiliated Hospital with Nanjing Medical University | P4 | B |
| Pioglitazone | National Institute on Aging (NIA) | P4 | B |
| Riluzole | Emory University | P4 | B |
+42 more in the Inflammatory Disease cohort
Other indications for Nepenthe
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cancer Of Unknown Primary Site | — | P4 | BBB · 75 |
| Chronic Pain Syndrome | — | P4 | BBB · 74 |
| Post-Operative Pain, Non-Human Animal | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nepenthe in Inflammatory Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nepenthe-inflammatory-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →